2026-04-17T03:43:11Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/106082025-10-24T10:29:21Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Cerezo Manchado, Juan José author Iturbe Hernández, Teodoro author Martínez Pacheco, María del Carmen author Gil Ortega, Ignacio author Campoy, Desirée author Canals Pernas, Tania author Olivera, Pável E. author 2023-11-15T08:45:00Z 2023-11-15T08:45:00Z 2023 COVID-19; Anticoagulation; Atrial fibrillation COVID-19; Anticoagulación; Fibrilación auricular COVID-19; Anticoagulació; Fibril·lació auricular Objective To assess the impact of new-onset atrial fibrillation (AF) on patients hospitalized with coronavirus disease 2019 (COVID-19). Methods Multicenter and retrospective study that included subjects >55 years hospitalized with COVID-19 from March to October 2020 in Spanish hospitals. Patients were divided into 3 groups (no AF, new-onset AF, and preexisting AF) and followed-up to 90 days. Results A total of 668 patients were included, of whom 162 (24.3%) had no AF, 107 (16.0%) new-onset AF and 399 (59.7%) preexisting AF. Compared to patients without AF, those patients with new-onset AF were older and had more comorbidities, but without differences with preexisting AF. During hospitalization, in the univariate analysis, compared to patients without AF, major bleeding and cardiovascular mortality were more frequent in patients with new-onset AF (10.3% vs 0.6%; P < .001; 2.8% vs 0.6%; P = .025, respectively), with a trend toward more stroke (1.9% vs 0%; P = .085). Outcomes were similar between AF groups, but the length of stay was greater in preexisting AF patients. Among patients with new-onset AF taking reduced doses of anticoagulant treatment was associated with higher risks of stroke and major bleeding. Conclusions In COVID-19 hospitalized patients, new-onset AF may be associated with worse outcomes, but influenced by the dose of anticoagulants. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Fundación para la Formación e Investigación Sanitarias de la Región de Murcia, though an unrestricted grant from Daichii Sankyo (DS) Spain. DS had no role in the design, analysis, interpretation and publication of the registry. http://hdl.handle.net/11351/10608 Anticoagulants (Medicina) - Ús terapèutic Malalties - Factors de risc COVID-19 (Malaltia) Fibril·lació auricular - Tractament CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Hematologic Agents::Anticoagulants DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Arrhythmias, Cardiac::Atrial Fibrillation DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos hematológicos::anticoagulantes ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::arritmias cardíacas::fibrilación atrial ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19: Results of the “ACO-VID” Registry